Enrique Bernal

Murcia, MU, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Correction: Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Correction: Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Journal: PloS one

Published: July 24, 2026

CABO-CHANCE study: A real-life world study of Cabotegravir plus Rilpivirine long-acting intramuscular in ART-experienced people with HIV.

CABO-CHANCE study: A real-life world study of Cabotegravir plus Rilpivirine long-acting intramuscular in ART-experienced people with HIV.

Journal: International journal of antimicrobial agents

Published: April 27, 2026

Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007-2023).

Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007-2023).

Journal: Open forum infectious diseases

Published: March 13, 2026

Early Fc-effector antibody signatures impact COVID-19 disease trajectory.

Early Fc-effector antibody signatures impact COVID-19 disease trajectory.

Journal: medRxiv : the preprint server for health sciences

Published: February 27, 2026

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Journal: AIDS (London, England)

Published: November 20, 2025

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.

Journal: AIDS (London, England)

Published: November 20, 2025

Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.

Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.

Journal: HIV medicine

Published: November 19, 2025

Case series of Oropouche fever among travellers returning from Cuba to Spain, 2024.

Case series of Oropouche fever among travellers returning from Cuba to Spain, 2024.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: October 17, 2025

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Journal: PloS one

Published: July 11, 2025

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Journal: PloS one

Published: July 11, 2025

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study).

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study).

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 24, 2025

Unveiling altered CD8 T-cell metabolism and homeostatic proliferation behind a low CD4/CD8 ratio in ART-suppressed HIV individuals with normal CD4 recovery.

Unveiling altered CD8 T-cell metabolism and homeostatic proliferation behind a low CD4/CD8 ratio in ART-suppressed HIV individuals with normal CD4 recovery.

Journal: Frontiers in immunology

Published: April 25, 2025

Showing 1-12 of 89

Last Updated: 09/26/2026